Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 717447 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
Send to Friend
Enquire before Buying
Electronic  Add to Basket
Hard Copy  Add to Basket



Dr Reddy's Laboratories Generics Company Intelligence Report
Espicom Business Intelligence Ltd, March 2009, Pages: 20


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Dr Reddy’s is the second largest pharmaceutical manufacturer in India, behind Ranbaxy. The company sells APIs, branded drugs and generics. Most of its branded drugs are copies of drugs patented in the West, but not in India.

The company’s current best selling active pharmaceutical ingredients include finasteride, with sales worth Rs952 million, ramipril, with sales worth Rs933 million, and ciprofloxacin, with sales worth Rs818 million. Sales of olanzapine were also fruitful in the latest fiscal year, rising by 359% to Rs721 million.

Dr Reddy’s is also represented in Western Europe, Russia and Asia. In 2002, the company made its first overseas acquisitions, both in the UK. In November 2005, Dr Reddy’s announced it had signed a definitive agreement to acquire Roche’s API business in Cuernavaca, Mexico. In March 2006, Dr Reddy’s completed its purchase of the German generic pharmaceutical firm, betapharm, from 3i, in a deal worth 480 million euros in cash. In 2007, the company announced that it was making the UK its European headquarters.

In April 2008, Dr Reddy’s agreed to acquire BASF’s pharmaceutical contract manufacturing business and related facility in Shreveport, Louisiana. During the same period, Dow Chemical finalised the sale of its Dowpharma Small Molecules business associated with its UK sites to Dr Reddy’s. Dr Reddy’s also acquired the Pisa, Italy-based Jet Generici.

In March 2009, Dr Reddy’s announced that it had realigned its Global Generics finished dosages strategy to focus on certain key countries and gradually exit some of the smaller markets. The company will remain in the US, India, Russia and the CIS, and Germany, along with another ten to 15 markets. At the same time, the firm announced that it had crossed the US$150 million milestone of revenues in Russia and the CIS region for FY2009.



Customers who bought this item also bought

D.R. Horton Inc - Company Profile, Financials and Condensed Data

Pharmaceutical Outsourcing in Drug Discovery and Development: Contract Research Opportunity in India

Opportunities and Challenges for Generic Drugs in the UK 2007

Pliva Generics Company Intelligence Report

India Business and Investment Report - May 2006 Edition

India Pharmaceuticals and Healthcare Report Q1 2008

Analyzing the Indian Pharmaceutical Industry

World Digital Radiography (DR) Markets



Top of page


   All rights reserved. ? Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds